A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
Status:
Completed
Trial end date:
2012-11-08
Target enrollment:
Participant gender:
Summary
This multiple dose study will assess the safety, tolerability, pharmacokinetics and
pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)-
infected participants. The primary hypothesis is that administration of grazoprevir for 7
days is sufficiently safe and well tolerated in HCV-infected males.